FDOPA PET and Nutritional Support in Parkinson's Disease
Status:
Active, not recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The overall goal of this study will be to further our understanding of how N Acetyl Cysteine
(NAC) can help to support dopaminergic function in patients with Parkinson's disease (PD). We
plan to use pre and post Positron emission tomography magnetic resonance imaging (PET-MRI)
with [F-18] Fluorodopa (FDOPA) to measure dopamine function, serum measures of NAC
concentrations, magnetic resonance spectroscopy (MRS) to measure inflammatory and oxidative
stress markers, and neurological measures to assess clinical symptoms, in patients with PD
who are given oral capsules plus IV infusions of NAC in addition to standard of care for PD
for 6 months in an open label cross over design.